

Prylutska, Svitlana; Politenkova, Svitlana; Afanasieva, Kateryna; Korolovych, Volodymyr; Bogutska, Kateryna; Sivolob, Andriy; Skivka, Larysa; Evstigneev, Maxim; Kostjukov, Viktor; Prylutsky, Yuriy; Ritter, Uwe

A nanocomplex of C60 fullerene with cisplatin : design, characterization and toxicity

Original published in:

Beilstein journal of nanotechnology, ISSN 2190-4286, ZDB-ID 2583584-1. - Frankfurt, M : Beilstein-Institut zur Förderung der Chemischen Wissenschaften. - 8 (2017), p. 1494-1501.

Original published: 2017-07-2

ISSN: 2190-4286

DOI: [10.3762/bjnano.8.149](https://doi.org/10.3762/bjnano.8.149)

URL: <https://doi.org/10.3762/bjnano.8.149>

[Visited: 2018-09-04]



This is an open access article licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, even commercially as long as the original work is properly cited.



A nanocomplex of C₆₀ fullerene with cisplatin: design, characterization and toxicity

Svitlana Prylutska^{*1}, Svitlana Politenkova¹, Kateryna Afanasieva¹, Volodymyr Korolovych², Kateryna Bogutska¹, Andriy Sivolob¹, Larysa Skivka¹, Maxim Evstigneev^{*3,4}, Viktor Kostjukov⁴, Yuriy Prylutskyi¹ and Uwe Ritter⁵

Full Research Paper

[Open Access](#)

Address:

¹Taras Shevchenko National University of Kyiv, Volodymyrska Str., 64, 01601 Kyiv, Ukraine, ²School of Materials Science and Engineering, Georgia Institute of Technology, Atlanta, USA, ³Belgorod State University, Pobedy Str. 85, 308015 Belgorod, Russia, ⁴Department of Physics, Sevastopol State University, Sevastopol 299053, Crimea and ⁵Technical University of Ilmenau, Institute of Chemistry and Biotechnology, Weimarer Str., 25, 98693 Ilmenau, Germany

Email:

Svitlana Prylutska^{*} - psvit@bigmir.net; Maxim Evstigneev^{*} - max_evstigneev@mail.ru

* Corresponding author

Keywords:

atomic force microscopy; C₆₀ fullerene; cisplatin; comet assay; computer simulation; dynamic light scattering; flow cytometry; human lymphocytes; toxicity in vitro

Beilstein J. Nanotechnol. **2017**, *8*, 1494–1501.

doi:10.3762/bjnano.8.149

Received: 08 March 2017

Accepted: 30 June 2017

Published: 20 July 2017

This article is part of the Thematic Series "Nanomaterial-based cancer theranostics".

Guest Editor: V. Sivakov

© 2017 Prylutska et al.; licensee Beilstein-Institut.

License and terms: see end of document.

Abstract

The self-organization of C₆₀ fullerene and cisplatin in aqueous solution was investigated using the computer simulation, dynamic light scattering and atomic force microscopy techniques. The results evidence the complexation between the two compounds. The genotoxicity of C₆₀ fullerene, Cis and their complex was evaluated in vitro with the comet assay using human resting lymphocytes and lymphocytes after blast transformation. The cytotoxicity of the mentioned compounds was estimated by Annexin V/PI double staining followed by flow cytometry. The results clearly demonstrate that water-soluble C₆₀ fullerene nanoparticles (0.1 mg/mL) do not induce DNA strand breaks in normal and transformed cells. C₆₀ fullerene in the mixture with Cis does not influence genotoxic Cis activity in vitro, affects the cell-death mode in treated resting human lymphocytes and reduces the fraction of necrotic cells.

Introduction

The water-soluble inorganic bi-valent platinum derivative, cisplatin (*cis*-[Pt(II)(NH₃)₂Cl₂], Cis), is currently one of the most effective therapeutic agents used against cancer diseases,

in particular, ovarian cancer, bladder cancer, esophagus cancer, lung cancer, and cancer of head and neck [1]. As an antitumor metal-containing agent Cis exerts an alkylating action and binds

covalently to DNA. In tumor cells Cis induces the selective inhibition of DNA synthesis and replication [2]. However, the action of Cis is accompanied by side effects that limit the use of Cis in anticancer chemotherapy. Cis-induced nephro-, hepato- and cardiotoxicity, as well as disorders of the central nervous system and sensory organs were reported [1]. Hence, there is a search for new drugs including nanodimensional compounds that could lower the side effects of Cis action, deliver Cis to the region of pathological process in a targeted manner, manage the curing at cell level, increase solubility in bioavailable form and protect Cis from degradation [3-9]. The carbon allotrope C₆₀ fullerene could act as such a potent agent.

Pristine C₆₀ fullerenes have no acute or sub-acute toxicity in vitro [10-12] and in vivo [13] (at least at low physiological concentrations), exerting strong antioxidant properties due to their high activity as free radical acceptors [14,15]. Water-soluble pristine C₆₀ fullerenes penetrate through plasma membranes and are located in the central part of tumor cells [16]. Thereby, C₆₀ fullerenes can be used for treatment of cancer [17,18], including combination chemotherapy [19] and photodynamic therapy [20-22]. They are also applied for the targeted delivery of drugs into tumor cells [23-25].

However, there are several conflicting reports in the literature regarding the genotoxicity of C₆₀ fullerene [26]. Thus, a strong correlation between the genotoxic response and the concentration of an aqueous suspension of nC₆₀ (178 nm in size) was observed at 2.2 µg/L in human lymphocytes using a single-cell gel electrophoresis assay [27]. In contrast, with stable C₆₀ fullerene suspensions in 0.1% carboxymethylcellulose sodium or 0.1% Tween 80 aqueous solution no positive mutagenic response was observed up to the dose of 1 mg/plate with any tester strain in the bacterial genotoxicity tests in vitro and in vivo [28].

The aqueous suspension of C₆₀ fullerenes caused positive responses in two bacterial genotoxicity tests, namely the *Bacillus subtilis* Rec-assay and umu test, up to concentrations of 0.048 mg/L and 0.43 mg/L, respectively. In [29], bulky DNA adducts could not be found by ³²P-postlabeling/polyacrylamide gel electrophoresis assay, suggesting that an aqueous suspension of C₆₀ fullerenes has the potential to damage DNA. By use of a comet assay it was also demonstrated that an aqueous suspension of C₆₀ fullerenes (0.1–1 mg/L) causes a concentration-dependent increase in DNA strand breaks in haemocytes [30].

The in vivo genotoxicity of C₆₀ fullerene was estimated with a comet assay in lung cells of rats. After a single and repeated instillation inflammatory responses were observed in the lungs, suggesting that C₆₀ fullerene has no potential for DNA damage

even at inflammation causing doses [31]. Thus, it may be concluded that the genotoxicity of C₆₀ fullerene in vitro and in vivo systems may strongly depend on its concentration in biomedium, dose administration, type of cells and time of exposure.

Since the biological action of C₆₀ fullerene significantly differs from the action of traditional drugs by the mechanism of penetration inside cells and biodistribution [23-25,32-35], the conjugation of C₆₀ molecules with drugs is currently considered a perspective biomedical strategy. The formation of a stable non-covalent nanocomplex of C₆₀ fullerene with doxorubicin (C₆₀+Dox) in aqueous solution was confirmed theoretically and experimentally [23,34,36]. The antitumor action of the C₆₀+Dox nanocomplex was reported to be stronger than the sole action of Dox or C₆₀ fullerene in vivo [23,24]. Moreover, recently it was found that C₆₀ fullerene in C₆₀+Dox nanocomplex prevents cyto- and genotoxic effects of Dox on lymphocytes in vitro [37,38]. Based on these results it was suggested that the mechanism of complexation could induce biological synergy for other drugs administered together with C₆₀ fullerene as well [19,23]. Taking into account the importance of Cis in chemotherapy of cancer, this drug could be a candidate molecule for study. A recent extended physico-chemical study has confirmed the formation of non-covalent entropically driven nanocomplexes between Cis and C₆₀ fullerene in physiological solution (i.e., the adsorption of Cis in C₆₀ fullerene clusters) [25,39]. Hence, it is reasonable to expect the biological interaction of these drugs. In order to testify this hypothesis in the present study we evaluated and compared in vitro cytotoxic action of C₆₀ fullerene, Cis and their complex on lymphocytes from healthy persons, as well as their genotoxic effects towards resting lymphocytes and lymphocytes after blast transformation.

Experimental

Materials preparation

A highly stable reproducible aqueous colloid solution of pristine C₆₀ fullerene (C₆₀FAS) with a maximum concentration of 0.15 mg/mL was prepared according to the protocol [40,41]. The initial stock solution of Cis (“Cisplatin-TEVA”, Pharmachemie B.V.) was prepared with a concentration of 0.5 mg/mL and was further diluted to the required concentrations used in particular experiments.

Immobilization of Cis on C₆₀ fullerene was accomplished according to the following protocol: C₆₀FAS and Cis solution were mixed in a molar ratio of 1:2.4 (typically 0.1 mM C₆₀ fullerene and 0.24 mM Cis). The obtained mixture was subjected to ultrasonic treatment in dispersant for 20 min, followed by magnetic stirring over 12 h at room temperature.

Computer simulation

The spatial structure of the C₆₀ fullerene was built according to [<http://www-jmg.ch.cam.ac.uk/data/molecules/misc/c60.html>]. The spatial structure of Cis was built with the aid of HyperChem 8.0 according to Wysokiński et al. [42] and then optimized in Gaussian 09W at the mPW1PW hybrid level of theory [43] in LanL2DZ basis set [44]. This level of theory and basis set is considered to be optimal for quantum-mechanical calculations of the molecules containing platinum atoms, in particular for Cis [42]. The spatial structure of the C₆₀+Cis nanocomplex was built according to Kostjukov et al. [45] with the aid of the XPLOR software (version 3.851 [46] with CHARMM27 force field). The plane of the Cis molecule was located parallel to the surface of the C₆₀ fullerene at a distance of ca. 3.4 Å. Geometry optimization of the C₆₀+Cis nanocomplex was accomplished by means of molecular mechanics in X-PLOR. The modeling of the aqueous environment was carried out by water molecules in the form of TIP3P placed in a cubic box with a side length of 35 Å (1423 molecules).

DLS study

Measurement of the hydrodynamic size distribution was performed by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern Ins. Ltd) with upload of multiple narrow modes (high resolution) at room temperature. The instrument is equipped with a He–Ne gas laser (max. output power 5 mW) operating at a wavelength of 633 nm. The measurements were performed at a 173° scattering angle (NIBS technology). The autocorrelation function of the scattered light intensity was analyzed by the Malvern Zetasizer software.

The zeta potential was measured with a Zetasizer Nano ZS (Malvern Ins. Ltd) using a universal dip cell in disposable cuvettes. The Smoluchowski approximation was used to convert the electrophoretic mobility to the zeta potential.

AFM study

The surface morphology of the particles was examined using atomic force microscopy (AFM). AFM images were collected using an Integra Spectra microscope (NTMDT, Russia) in the “light” tapping mode according to the well-established procedure. For the sample preparation, a drop of solution was placed onto a pre-cleaned microscope glass slide and dried in air prior to AFM imaging.

Cell isolation and cultivation

Human peripheral blood from healthy donors was collected into a heparinized medical syringe. Lymphocytes were separated by centrifugation in a density gradient (Histopaque 1077, Sigma, USA) according to instructions of the manufacturer and washed twice: control lymphocytes in 0.15 M NaCl, lymphocytes that

were intended for blast transformation reaction in RPMI 1640 medium. To induce the blast transformation the lymphocyte suspension was cultivated in RPMI 1640 medium with 10% FBS and 1000 units/mL IL-2 α at 37 °C for 20 h. After cultivation the cells were washed in 0.15 M NaCl. Aliquots of the suspension were used for cytological analysis to evaluate the level of blast transformation (the fraction of lymphoblasts).

Incubation of lymphocytes and lymphoblasts

The cell suspension in RPMI 1640 medium (cell concentration in the range of 1×10^5 to 5×10^5 cells per mL) was incubated in the presence of either C₆₀ fullerene (0.1 mg/mL), anticancer drug Cis (0.01, 0.1 or 0.15 mg/mL) or the complex of C₆₀ fullerene with Cis (Cis concentration was 0.1 or 0.15 mg/L, the C₆₀ fullerene to Cis molar ratio was equal to 1:2.4) for 1.5 h at 37 °C, washed once in 0.15 M NaCl, and then used for the comet assay. Five to seven independent repeats of the experiments were performed. As shown before [25], the molar ratio of 1:2.4 yields the highest anticancer activity of the C₆₀+Cis complex and was therefore used in the experiments.

Comet assay

To obtain lysed cells (nucleoids) 20 μ L of the cell suspension was mixed with 40 μ L of 1% low-melting agarose (Sigma, USA) at ca. 37 °C. 20 μ L of the mixture were used to prepare a microscope slide previously covered with 1% high-melting agarose. After agarose polymerization, the slides were placed in the lysis solution consisting of 2.5 M NaCl, 100 mM EDTA, 10 mM Tris-HCl (pH 7.5), and 1% Triton X-100 (Ferak, Germany), which was added before use. Cells were exposed to lysis solution for 2 h at 4 °C. After the lysis, slides were washed with TBE buffer (89 mM Tris-borate, 2 mM EDTA, pH 7.5) and electrophoresed in the same buffer for 20 min at 4 °C (1 V/cm, 300 mA).

After electrophoresis, the slides were stained with 1.3 μ g/mL of DAPI (Sigma, USA) and immediately analyzed under a fluorescence microscope (LOMO, Russia) connected with Canon A570 camera (a total 200 to 300 cells on each slide were analyzed). The relative amount of DNA in the comet tail, the parameter that reflects the level of DNA damages, was determined using the image analysis software programs Comet Assay IV (Perspective Instruments, UK) and CometScore (TriTec Corp., USA).

Cell-death assay

Apoptosis was assessed by staining cells with Annexin V–fluorescein isothiocyanate (FITC) and counterstaining with propidium iodide (PI) with the use Annexin V-FITC Apoptosis Detection Kit (Dojindo EU GmbH, Munich, Germany) according to the instructions of the manufacturer. Briefly, 2×10^5 cells

were placed into wells of a 96-well flat-bottom plate and were treated with C₆₀ fullerene (sample 1), Cis (sample 2) and C₆₀+Cis nanocomplex (sample 3) for 24 h. All additives were used at the concentration of 0.15 mg/mL. Untreated cells were used as a control (sample 4). Afterwards cells were washed twice with PBS and incubated in the Annexin V binding buffer containing 1/50 volume of FITC-conjugated Annexin V solution and PI (50 µg/mL) for 10 min at room temperature in the dark. Cells from each sample were then analyzed by FACS Calibur flow cytometer (BD Biosciences). The data were analyzed using CELLQuest software (BD). PI detects cells that have lost CPM integrity (i.e., necrotic and secondary necrotic cells), whereas Annexin V detects early apoptotic cells.

Statistics

Statistical analysis was performed by conventional methods of variation statistics. Significance of the differences between the control and experimental measurements was estimated within the framework of the Student's t-test using Origin 8.0 software (OriginLab Corporation, USA). The difference between the compared values was considered to be significant at $p < 0.05$.

Results and Discussion

Characterization of the C₆₀+Cis mixture

The freshly prepared mixture of C₆₀ fullerene with Cis was characterized by conventional physico-chemical methods, namely DLS and AFM. The monitoring of the morphology of nanoparticles in solution is important not only for checking the quality of solution for study, but also to control the degree of aggregation which may influence their biodistribution and toxicity [47].

Figure 1 shows DLS data of C₆₀FAS and C₆₀+Cis mixture at room temperature. It is seen that C₆₀FAS contains C₆₀ fullerene nanoparticles with hydrodynamic sizes ranging from 65 to 105 nm. The C₆₀+Cis nanocomplex exhibits hydrodynamic sizes from 91 to 164 nm. The Z-average size of the C₆₀+Cis nanocomplex is about 122 nm. These results are in accordance with AFM data (Figure 2), as well as with previous study of C₆₀+Cis complexation [39].

The zeta potential of the C₆₀+Cis mixture measured in this work equals to -16.8 mV at room temperature. It is known from previous studies that C₆₀ fullerene clusters not containing any guest molecules have a zeta potential equal to -23 mV in water solution [41]. Addition of neutral Cis molecules into C₆₀FAS results in their adsorption into the C₆₀ fullerene clusters and causes a lowering of the absolute value of the zeta potential. The stability of such negatively charged clusters in water is determined by two opposite forces, viz., electrostatic repulsion of negatively charged C₆₀ molecules and attraction of the




Figure 1: DLS (hydrodynamic size) results of C₆₀FAS (grey; concentration 0.15 mg/mL) and C₆₀+Cis mixture (red; molar ratio of 1:2.4).




Figure 2: AFM images of a) nanoparticles in C₆₀FAS (concentration 0.15 mg/mL) and b) C₆₀+Cis mixture (molar ratio as 1:2.4).

C₆₀ fullerenes due to hydrophobic and van der Waals forces. Thereby, the negative potential of C₆₀+Cis clusters is an important factor responsible for the stabilization of this aqueous system.

The structural and energetic peculiarities of C₆₀+Cis complexation were investigated by calculating the energy-minimized spatial structure of their complex, shown in Figure 3.




Figure 3: The calculated energy-optimized structure of the C_{60} +Cis nanocomplex in aqueous solution.

The initial location coordinates of Cis above the C_{60} fullerene surface were taken from the ab initio structure [39]. Then we performed the molecular dynamics simulation of this nanocomplex in aqueous environment and calculated the time-averaged energies of interaction. The net van der Waals, electrostatic and hydrophobic energies were obtained as follows, $\Delta G_{vdw} \approx -0.6$ kJ/mol, $\Delta G_{el} \approx 0.9$ kJ/mol and $\Delta G_{hyd} \approx -9.0$ kJ/mol, respectively. The near-zero magnitudes of the net 'vdw' and 'el' terms are quite expected and originate from compensatory nature of the enthalpic interaction with water environment and between the interacting molecules (discussed in more detail in [36,39]). The 'hyd' term outweighs any other interactions indicating the predominantly entropic character of C_{60} +Cis complexation. The obtained results fully agree with previous calorimetric measurements of the same system [39] reporting the purely hydrophobic nature of interaction between these molecules. Moreover, the same conclusion was made regarding the aggregation of C_{60} fullerene in solution [48], C_{60} fullerene

complexation with Dox [36] and landomycin A [49], and seems to reveal a general pattern of complexation of small molecules in water [45].

Estimation of genotoxic effects

Figure 4 shows typical images of the comet assay obtained after 20 min of electrophoresis of lysed cells. For both lymphocytes and lymphoblasts, either the control cells or cells treated with the agents studied, we did not observe any differences in the comet appearance.




Figure 4: The representative comet-assay images obtained after 20 min of electrophoresis of a) control cells, b) cells incubated with C_{60} fullerene at concentration of 0.1 mg/mL, and c) cells treated with Cis at 0.15 mg/mL. The bars correspond to 10 μ m.

The average amount of DNA in the comet tails in control experiments, when the isolated lymphocytes or lymphoblasts were incubated in RPMI 1640 medium without any agents, was ca. 0.11 for both cell types (Figure 5). This value, which appears to




Figure 5: The relative amount of DNA in the comet tails (P) after 20 min of electrophoresis of a) lymphocytes and b) lymphoblasts treated with Cis, C_{60} fullerene or C_{60} +Cis nanocomplex. Control: cells were incubated in RPMI 1640 medium without any additional agents. The average values of 5–7 independent experiments are presented. The error bars represent the standard deviations. *Statistically significant ($p < 0.05$) with respect to control cells.

be slightly higher than that usually observed for intact cells (the typical value is 0.06–0.07) [50], may indicate that a small amount of DNA strand breaks occurred in the cells. We did not observe any significant changes in the average amount of DNA in the comet tails after cell treatment with C₆₀ fullerene (Figure 5). Thus, C₆₀ fullerene nanoparticles do not induce the DNA breaks in the cells.


At a low Cis concentration (0.01 mg/mL) the Cis-treated lymphocytes and lymphoblasts showed a DNA amount in the tails comparable to that of control cells. The same picture was observed for lymphocytes treated with Cis at 0.1 mg/mL (Figure 5a), but a significant decrease in the DNA fraction in the comet tails was detected for lymphoblasts incubated with Cis at this concentration. To explain this result it is worth remembering the mechanism of Cis action. After penetration into cell nuclei Cis may induce coordinate bonds between Pt and guanine bases in DNA that leads to intra- and inter-strand crosslinking. In addition, Cis interaction with nuclear proteins induces DNA–protein crosslinking. After cell lysis these crosslinks remain in nucleoids, which hamper DNA migration in the comet tail under electrophoretic conditions, i.e., the lower the fraction of DNA in the tail, the stronger the mutagenic action of Cis. Thus, lymphoblasts appear to be more sensitive to Cis action than lymphocytes. During cultivation with IL-2 α (when lymphocytes are transformed into lymphoblast) a large set of genes are activated to allow the entry of cells in the G1 phase of the cell cycle [51]. Probably, such transformation that never occurs in vivo in lymphocytes under normal conditions, leads to an increase in the cells' sensitivity to the anticancer drug Cis.

The increase of the Cis concentration up to 0.15 mg/mL causes significant decrease in the DNA fraction in the comet tails for both cell types, viz., the average amount of DNA in the tail was 0.08 ± 0.01 for lymphocytes and 0.05 ± 0.01 for lymphoblasts. At the same time, we did not observe any differences in DNA fraction in the comet tail between cells treated with Cis only or with its nanocomplex with C₆₀ fullerene. Hence, C₆₀ fullerene in the nanocomplex does not influence the Cis activity.

Comparative evaluation of the cytotoxic effects

Genotoxic effect of Cis is mostly associated with apoptotic cell death. However, mechanism of Cis cytotoxic action involves multiple signaling pathways inducing not only apoptosis but also necrotic cell death [52–55]. Nephrotoxicity is considered to be the most important side effect of Cis and is mainly caused by tubular epithelial cell necrosis induced by extensive reactive oxygen species (ROS) generation [56,57]. According to Kaeidi et al. [58], preconditioning with mild oxidative stress may en-

hance some endogenous defense mechanisms and stimulate cellular adaptation to subsequent severe oxidative stress after the treatment with Cis. C₆₀ fullerene can either consume ROS or induce their generation [59]. Taking into account this fact we have hypothesized that C₆₀ fullerene in the nanocomplex with Cis can affect mode of cell death induced by Cis. In order to testify this hypothesis, Annexin V/PI double staining of human healthy lymphocytes treated with either C₆₀ fullerene, Cis or their nanocomplex was conducted. As shown in Figure 6, the total number of dead lymphocytes from healthy persons after the treatment with C₆₀ fullerene was 13.8% vs 32.4% and 36.7% in samples of cells treated with Cis and C₆₀+Cis nanocomplex, respectively.



Analysis of cell death using an Annexin V-FITC/PI assay allows one to differentiate the stages of apoptosis and to reveal necrotic cells. The treatment of human healthy resting lymphocytes with C₆₀ fullerene resulted in significant increase of early apoptotic cells (An+PI–) to 11.8%, and raise of late apoptotic (An+PI+) to 1.7% on average, as well as necrotic cells (An–PI+) to 0.3%. Apoptosis to necrosis ratio in these samples was 6:1 (on average). In cell samples treated with Cis we noticed significantly more necrotic cells (9.2%), wherein apoptosis to necrosis ratio was 2:1. C₆₀+Cis nanocomplex induced mainly apoptosis in resting lymphocytes, and apoptosis to necrosis ratio was 7:1.

Conclusion

1. The computer simulation, DLS and AFM data confirmed the ability of C₆₀ fullerene to form non-covalent nanocomplex with Cis in aqueous solution.

2. C₆₀ fullerene nanoparticles do not induce DNA strand breaks in the normal (lymphocytes) and transformed (lymphoblasts) cells as revealed by the comet assay.
3. C₆₀ fullerene in the C₆₀+Cis nanocomplex does not influence the genotoxic activity of Cis in vitro.
4. C₆₀ fullerene in the C₆₀+Cis nanocomplex affects the cell death mode in treated resting lymphocytes from healthy persons and reduces the fraction of necrotic cells.

Acknowledgements

S.V.P. is grateful to the Academician Platon Kostyuk Foundation for financial support. This work was partially supported by STCU project N 6256.

References

1. Florea, A.-M.; Büsselberg, D. *Cancer* **2011**, *3*, 1351–1371. doi:10.3390/cancers3011351
2. Cepeda, V.; Fuertes, M. A.; Castilla, J.; Alonso, C.; Quevedo, C.; Pérez, J. M. *Anti-Cancer Agents Med. Chem.* **2007**, *7*, 3–18. doi:10.2174/187152007779314044
3. Dong, X.-P.; Xiao, T.-H.; Dong, H.; Jiang, N.; Zhao, X.-G. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 3079–3083. doi:10.7314/APJCP.2013.14.5.3079
4. Pandey, A.; Sarangi, S.; Chien, K.; Sengupta, P.; Papa, A.-L.; Basu, S.; Sengupta, S. *Nanotechnology* **2014**, *25*, 445101. doi:10.1088/0957-4484/25/44/445101
5. Liao, L.; Liu, J.; Dreaden, E. C.; Morton, S. W.; Shopsowitz, K. E.; Hammond, P. T.; Johnson, J. A. *J. Am. Chem. Soc.* **2014**, *136*, 5896–5899. doi:10.1021/ja502011g
6. Alam, N.; Khare, V.; Dubey, R.; Saneja, A.; Kushwaha, M.; Singh, G.; Sharma, N.; Chandan, B.; Gupta, P. N. *Mater. Sci. Eng., C* **2014**, *38*, 85–93. doi:10.1016/j.msec.2014.01.043
7. Guo, S.; Miao, L.; Wang, Y.; Huang, L. *J. Controlled Release* **2014**, *174*, 137–142. doi:10.1016/j.jconrel.2013.11.019
8. Yoong, S. L.; Wong, B. S.; Zhou, Q. L.; Chin, C. F.; Li, J.; Venkatesan, T.; Ho, H. K.; Yu, V.; Ang, W. H.; Pastorin, G. *Biomaterials* **2014**, *35*, 748–759. doi:10.1016/j.biomaterials.2013.09.036
9. He, C.; Liu, D.; Lin, W. *Biomaterials* **2015**, *36*, 124–133. doi:10.1016/j.biomaterials.2014.09.017
10. Prylutska, S. V.; Matyshevska, O. P.; Golub, A. A.; Prylutsky, Y. I.; Potebnya, G. P.; Ritter, U.; Scharff, P. *Mater. Sci. Eng., C* **2007**, *27*, 1121–1124. doi:10.1016/j.msec.2006.07.009
11. Prylutska, S. V.; Grynyuk, I. I.; Grebinyk, S. M.; Matyshevska, O. P.; Prylutsky, Y. I.; Ritter, U.; Siegmund, C.; Scharff, P. *Materialwiss. Werkstofftech.* **2009**, *40*, 238–241. doi:10.1002/mawe.200900433
12. Tolkachov, M.; Sokolova, V.; Loza, K.; Korolovych, V.; Prylutsky, Y.; Epple, M.; Ritter, U.; Scharff, P. *Materialwiss. Werkstofftech.* **2016**, *47*, 216–221. doi:10.1002/mawe.201600486
13. Baati, T.; Bourasset, F.; Gharbi, N.; Njim, L.; Abderrabba, M.; Kerkeni, A.; Szwarc, H.; Moussa, F. *Biomaterials* **2012**, *33*, 4936–4946. doi:10.1016/j.biomaterials.2012.03.036
14. Gharbi, N.; Pressac, M.; Hadchouel, M.; Szwarc, H.; Wilson, S. R.; Moussa, F. *Nano Lett.* **2005**, *5*, 2578–2585. doi:10.1021/nl051866b
15. Prylutska, S. V.; Grynyuk, I. I.; Matyshevska, O. P.; Prylutsky, Y. I.; Ritter, U.; Scharff, P. *Fullerenes, Nanotubes, Carbon Nanostruct.* **2008**, *16*, 698–705. doi:10.1080/15363830802317148
16. Prylutska, S.; Bilyy, R.; Overchuk, M.; Bychko, A.; Andreichenko, K.; Stoika, R.; Rybalchenko, V.; Prylutsky, Y.; Tsierkezos, N. G.; Ritter, U. *J. Biomed. Nanotechnol.* **2012**, *8*, 522–527. doi:10.1166/jbn.2012.1404
17. Prylutska, S. V.; Burlaka, A. P.; Prylutsky, Y. I.; Ritter, U.; Scharff, P. *Exp. Oncol.* **2011**, *33*, 162–164.
18. Didenko, G.; Prylutska, S.; Kichmarenko, Y.; Potebnya, G.; Prylutsky, Y.; Slobodyanik, N.; Ritter, U.; Scharff, P. *Materialwiss. Werkstofftech.* **2013**, *44*, 124–128. doi:10.1002/mawe.201300082
19. Prylutska, S.; Grynyuk, I.; Matyshevska, O.; Prylutsky, Y.; Evstigneev, M.; Scharff, P.; Ritter, U. *Drugs R&D* **2014**, *14*, 333–340. doi:10.1007/s40268-014-0074-4
20. Scharff, P.; Carta-Abelmann, L.; Siegmund, C.; Matyshevska, O. P.; Prylutska, S. V.; Koval, T. V.; Golub, A. A.; Yashchuk, V. M.; Kushnir, K. M.; Prylutsky, Y. I. *Carbon* **2004**, *42*, 1199–1201. doi:10.1016/j.carbon.2003.12.055
21. Davydenko, M. O.; Radchenko, E. O.; Yashchuk, V. M.; Dmytruk, I. M.; Prylutsky, Y. I.; Matyshevska, O. P.; Golub, A. A. *J. Mol. Liq.* **2006**, *127*, 145–147. doi:10.1016/j.molliq.2006.03.046
22. Jiao, F.; Liu, Y.; Qu, Y.; Li, W.; Zhou, G.; Ge, C.; Li, Y.; Sun, B.; Chen, C. *Carbon* **2010**, *48*, 2231–2243. doi:10.1016/j.carbon.2010.02.032
23. Panchuk, R. R.; Prylutska, S. V.; Chumak, V. V.; Skorokhyd, N. R.; Lehka, L. V.; Evstigneev, M. P.; Prylutsky, Y. I.; Berger, W.; Heffeter, P.; Scharff, P.; Ritter, U.; Stoika, R. S. *J. Biomed. Nanotechnol.* **2015**, *11*, 1139–1152. doi:10.1166/jbn.2015.2058
24. Prylutska, S. V.; Skivka, L. M.; Didenko, G. V.; Prylutsky, Y. I.; Evstigneev, M. P.; Potebnya, G. P.; Panchuk, R. R.; Stoika, R. S.; Ritter, U.; Scharff, P. *Nanoscale Res. Lett.* **2015**, *10*, 499. doi:10.1186/s11671-015-1206-7
25. Prylutska, S.; Panchuk, R.; Goluński, G.; Skivka, L.; Prylutsky, Y.; Hurmach, V.; Skorokhyd, N.; Borowik, A.; Woziwodzka, A.; Piosik, J.; Kyzyma, O.; Garamus, V.; Bulavin, L.; Evstigneev, M.; Buchelnikov, A.; Stoika, R.; Berger, W.; Ritter, U.; Scharff, P. *Nano Res.* **2017**, *10*, 652–671. doi:10.1007/s12274-016-1324-2
26. Wallin, H.; Jacobsen, N. R.; White, P. A.; Gingerich, J.; Møller, P.; Loft, S.; Vogel, U. *J. Biomed. Nanotechnol.* **2011**, *7*, 29. doi:10.1166/jbn.2011.1185
27. Dhawan, A.; Taurozzi, J. S.; Pandey, A. K.; Shan, W.; Miller, S. M.; Hashsham, S. A.; Tarabara, V. V. *Environ. Sci. Technol.* **2006**, *40*, 7394–7401. doi:10.1021/es0609708
28. Shinohara, N.; Matsumoto, K.; Endoh, S.; Maru, J.; Nakanishi, J. *Toxicol. Lett.* **2009**, *191*, 289–296. doi:10.1016/j.toxlet.2009.09.012
29. Matsuda, S.; Matsui, S.; Shimizu, Y.; Matsuda, T. *Environ. Sci. Technol.* **2011**, *45*, 4133–4138. doi:10.1021/es1036942
30. Al-Subiai, S. N.; Arlt, V. M.; Frickers, P. E.; Readman, J. W.; Stolpe, B.; Lead, J. R.; Moody, A. J.; Jha, A. N. *Mutat. Res.* **2012**, *745*, 92–103. doi:10.1016/j.mrgentox.2011.12.019
31. Ema, M.; Tanaka, J.; Kobayashi, N.; Naya, M.; Endoh, S.; Maru, J.; Hosoi, M.; Nagai, M.; Nakajima, M.; Hayashi, M.; Nakanishi, J. *Regul. Toxicol. Pharmacol.* **2012**, *62*, 419–424. doi:10.1016/j.yrtph.2012.01.003
32. Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; Wilson, L. J. *J. Am. Chem. Soc.* **2005**, *127*, 12508–12509. doi:10.1021/ja0546525

33. Lu, F.; Haque, S. A.; Yang, S.-T.; Luo, P. G.; Gu, L.; Kitaygorodskiy, A.; Li, H.; Lacher, S.; Sun, Y.-P. *J. Phys. Chem. C* **2009**, *113*, 17768–17773. doi:10.1021/jp906750z
34. Evstigneev, M. P.; Buchelnikov, A. S.; Voronin, D. P.; Rubin, Y. V.; Belous, L. F.; Prylutskyy, Y. I.; Ritter, U. *ChemPhysChem* **2013**, *14*, 568–578. doi:10.1002/cphc.201200938
35. Skamrova, G. B.; Laponogov, I.; Buchelnikov, A. S.; Shkhorbatov, Y. G.; Prylutskaya, S. V.; Ritter, U.; Prylutskyy, Y. I.; Evstigneev, M. P. *Eur. Biophys. J.* **2014**, *43*, 265–276. doi:10.1007/s00249-014-0960-2
36. Prylutskyy, Y. I.; Evstigneev, M. P.; Pashkova, I. S.; Wyrzykowski, D.; Woziwodzka, A.; Goluński, G.; Piosik, J.; Cherepanov, V. V.; Ritter, U. *Phys. Chem. Chem. Phys.* **2014**, *16*, 23164–23172. doi:10.1039/C4CP03367A
37. Prylutskaya, S. V.; Didenko, G. V.; Potebnya, G. P.; Bogutska, K. I.; Prylutskyy, Y. I.; Ritter, U.; Scharff, P. *Biopolym. Cell* **2014**, *30*, 372–376. doi:10.7124/bc.0008B4
38. Afanasieva, K. S.; Prylutskaya, S. V.; Lozovik, A. V.; Bogutska, K. I.; Sivolob, A. V.; Prylutskyy, Y. I.; Ritter, U.; Scharff, P. *Ukr. Biochem. J.* **2015**, *87*, 91–98. doi:10.15407/ubj87.01.091
39. Prylutskyy, Y. I.; Cherepanov, V. V.; Evstigneev, M. P.; Kyzyma, O. A.; Petrenko, V. I.; Styopkin, V. I.; Bulavin, L. A.; Davidenko, N. A.; Wyrzykowski, D.; Woziwodzka, A.; Piosik, J.; Kaźmierkiewicz, R.; Ritter, U. *Phys. Chem. Chem. Phys.* **2015**, *17*, 26084–26092. doi:10.1039/C5CP02688A
40. Prylutskyy, Y. I.; Durov, S. S.; Bulavin, L. A.; Adamenko, I. I.; Moroz, K. O.; Geru, I. I.; Dihor, I. N.; Scharff, P.; Eklund, P. C.; Grigorian, L. *Int. J. Thermophys.* **2001**, *22*, 943–956. doi:10.1023/A:1010791402990
41. Ritter, U.; Prylutskyy, Y. I.; Evstigneev, M. P.; Davidenko, N. A.; Cherepanov, V. V.; Senenko, A. I.; Marchenko, O. A.; Naumovets, A. G. *Fullerenes, Nanotubes, Carbon Nanostruct.* **2015**, *23*, 530–534. doi:10.1080/1536383X.2013.870900
42. Wysockiński, R.; Michalska, D. *J. Comput. Chem.* **2001**, *22*, 901–912. doi:10.1002/jcc.1053
43. Adamo, C.; Barone, V. *J. Chem. Phys.* **1998**, *108*, 664–675. doi:10.1063/1.475428
44. Hay, P. J.; Wadt, W. R. *J. Chem. Phys.* **1985**, *82*, 299–310. doi:10.1063/1.448975
45. Kostjukov, V. V.; Khomytova, N. M.; Hernandez Santiago, A. A.; Tavera, A.-M. C.; Alvarado, J. S.; Evstigneev, M. P. *J. Chem. Thermodyn.* **2011**, *43*, 1424–1434. doi:10.1016/j.jct.2011.04.014
46. Brunger, A. T. *X-PLOR. A system for X-ray crystallography and NMR*; Yale University Press: New Haven, CT, USA, 1992.
47. Cataldo, F.; Da Ros, T., Eds. *Medicinal Chemistry and Pharmacological Potential of Fullerenes and Carbon Nanotubes*; Springer: Netherlands, 2008. doi:10.1007/978-1-4020-6845-4
48. Voronin, D. P.; Buchelnikov, A. S.; Kostjukov, V. V.; Khrapaty, S. V.; Wyrzykowski, D.; Piosik, J.; Prylutskyy, Y. I.; Ritter, U.; Evstigneev, M. P. *J. Chem. Phys.* **2014**, *140*, 104909. doi:10.1063/1.4867902
49. Prylutskyy, Y. I.; Cherepanov, V. V.; Kostjukov, V. V.; Evstigneev, M. P.; Kyzyma, O. A.; Bulavin, L. A.; Ivankov, O.; Davidenko, N. A.; Ritter, U. *RSC Adv.* **2016**, *6*, 81231–81236. doi:10.1039/C6RA18807A
50. Afanasieva, K.; Chopei, M.; Zazhytska, M.; Vikhрева, M.; Sivolob, A. *Biochim. Biophys. Acta* **2013**, *1833*, 3237–3244. doi:10.1016/j.bbamcr.2013.09.021
51. Mzali, R.; Seguin, L.; Liot, C.; Auger, A.; Pacaud, P.; Loirand, G.; Thibault, C.; Pierre, J.; Bertoglio, J. *FASEB J.* **2005**, *19*, 1911–1930. doi:10.1096/fj.05-4030fje
52. Godoy, L. C.; Anderson, C. T. M.; Chowdhury, R.; Trudel, L. J.; Wogan, G. N. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 20373–20378. doi:10.1073/pnas.1218938109
53. Zhang, M. N.; Long, Y.-T.; Ding, Z. *J. Inorg. Biochem.* **2012**, *108*, 115–122. doi:10.1016/j.jinorgbio.2011.11.010
54. Hong, J.-Y.; Kim, G.-H.; Kim, J.-W.; Kwon, S.-S.; Sato, E. F.; Cho, K.-H.; Shim, E. B. *BMC Syst. Biol.* **2012**, *6*, No. 122. doi:10.1186/1752-0509-6-122
55. Zhang, J.; Lou, X.; Jin, L.; Zhou, R.; Liu, S.; Xu, N.; Liao, D. J. *Oncoscience* **2014**, *1*, 407–422. doi:10.18632/oncoscience.61
56. Sancho-Martínez, S. M.; Piedrafitá, F. J.; Cannata-Andía, J. B.; López-Novoa, J. M.; López-Hernández, F. J. *Toxicol. Sci.* **2011**, *122*, 73–85. doi:10.1093/toxsci/kfr098
57. Sancho-Martínez, S. M.; Prieto-García, L.; Prieto, M.; López-Novoa, J. M.; López-Hernández, F. J. *Pharmacol. Ther.* **2012**, *136*, 35–55. doi:10.1016/j.pharmthera.2012.07.003
58. Kaeidi, A.; Rasoulían, B.; Hajjalizadeh, Z.; Pourkhodadad, S.; Rezaei, M. *Renal Failure* **2013**, *35*, 1382–1386. doi:10.3109/0886022X.2013.829406
59. Kong, L.; Zepp, R. G. *Environ. Toxicol. Chem.* **2012**, *31*, 136–143. doi:10.1002/etc.711

License and Terms

This is an Open Access article under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The license is subject to the *Beilstein Journal of Nanotechnology* terms and conditions: (<http://www.beilstein-journals.org/bjnano>)

The definitive version of this article is the electronic one which can be found at: [doi:10.3762/bjnano.8.149](https://doi.org/10.3762/bjnano.8.149)